Business
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe eosinophilic asthma. The Company expects to report data from the BREADTH trial in late-2027. “Untreated asthma can result in long-term medical complications. We continue to hear from physicians and patients that new treatment options are desperately needed. Dosing the first patient in our BREADTH study marks an important step in advancing KT-621 as a novel oral treatment option for patients living with chronic, debilitating Type 2 diseases,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “This milestone builds on our compelling data and clinical progress and reflects our broader vision to deliver novel, convenient oral medicines with biologics-like activity for inflammatory diseases with significant unmet need including asthma.” The KT-621 BREADTH Phase 2b clinical trial is a global, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of three doses of KT-621 in approximately 264 adult patients with moderate to severe eosinophilic asthma over 12 weeks. Baseline eligibility criteria include an absolute blood eosinophil count of ≥300 cells/uL, fractional exhaled nitric oxide (FeNO) ≥25 ppb, and a pre-bronchodilator forced expiratory volume in one second (FEV1) 40 to 80% of predicted normal. The primary endpoint is the change from baseline in FEV1. Secondary endpoints will evaluate a range of additional safety, efficacy, and quality of life measures. More information on the BREADTH study can be found on clinicaltrials.gov (NCT# 07323654). The KT-621 BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis (AD) adolescent and adult patients is also ongoing. The Company expects to report data from the BROADEN2 trial by mid-2027. More in...